


HEALTHCARE

## **The Future of Personalized Medicine:**

The impact of proteomics on drug discovery and clinical trial design

By Dr C L Barton Ltd

Published by Business Insights

 [Table of Contents](#)

## **Dr CL Barton Ltd**

Dr CL Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Where applicable the research reports combine independent scientific analysis with patients- and prescription-based models to forecast the potential sales growth of key developmental drugs and isolate the key drivers within the pharmaceutical sector.

Dr CL Barton has over 10 year's practical pharmaceutical research experience with a leading pharmaceutical company and Pan-European Pharmaceutical analyst with a European Bank.

Copyright © 2005 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## The Future of Personalized Medicine: The Impact of Proteomics on Drug Discovery and Clinical Trial Design

<b>Executive summary</b>	<b>10</b>	
Introduction to proteomics	10	
Proteomic technologies	11	
Proteomic applications in drug discovery	12	
Proteomic applications in clinical trial design and personalized medicine	13	
Pharma and proteomic company alliances	13	
<b>Chapter 1</b>	<b>Introduction to proteomics</b>	<b>16</b>
Summary		16
Introduction		17
The human genome versus the proteome		19
Identification of human genome		19
Applications to proteomics		20
The relationship between the proteome and the genome		22
The genome		22
Proteins		23
From genes to proteins		26
Proteomics		28
Conclusions		29
<b>Chapter 2</b>	<b>Proteomic technologies</b>	<b>32</b>
Summary		32
Laboratory methods used in proteomics		33
Separation techniques		33
Identification techniques		33
Interactions techniques		33
Separation techniques		37

2-dimensional polyacrylamide gel electrophoresis (2-D PAGE)	37
Liquid chromatography (LC)	37
Protein arrays	38
Identification techniques	39
Mass spectrometry	39
Protein-protein interaction techniques	41
<b>Automation</b>	<b>42</b>
Pre-fractionation	42
Separation	43
Identification	44
Complete proteomics solutions	45
The future of automation in proteomics	45
<b>Conclusions</b>	<b>47</b>
<b>Bioinformatics and databases</b>	<b>48</b>
Data analysis	49
Databases	49
Laboratory information management systems (LIMS)	51
Conclusions	52
<b>Overall conclusions</b>	<b>52</b>

## **Chapter 3                    Proteomic applications in drug discovery                    56**

<b>Summary</b>	<b>56</b>
<b>Introduction</b>	<b>57</b>
<b>Optimizing the R&amp;D process</b>	<b>59</b>
<b>Early selection of efficacious and non-toxic drug targets</b>	<b>64</b>
Toxicoproteomics	66
Pharmacoproteomics	67
Conclusions	68
<b>Accelerating the discovery of new targets for therapeutic candidates</b>	<b>69</b>
Therapeutic proteins	69
Protein targets	73
Mining the proteome is an alternative approach for drug discovery	73
Conclusions	74

## **Chapter 4                    Proteomic applications in clinical trial design and personalized medicine                    76**

<b>Summary</b>	<b>76</b>
----------------	-----------





<b>References</b>	<b>146</b>
<b>Website references</b>	<b>153</b>

## List of Figures

Figure 1.1:	Nearly 500 proteins identified through proteomics have known functions in disease	20
Figure 1.2:	The basic structure of the (unwound) DNA helix	22
Figure 1.3:	The general structure of an amino acid and peptide bond	24
Figure 1.4:	The active site of the bacterial serine protease subtilisin	25
Figure 1.5:	The process of protein synthesis	26
Figure 2.6:	Techniques used in proteomics	35
Figure 2.7:	The role and scope of bioinformatics in proteomics research	48
Figure 3.8:	Only 30% of drugs produce revenues that exceed the average R&D cost	59
Figure 3.9:	Industry average attrition curves, 2004	60
Figure 3.10:	US pharmaceutical industry R&D expenditure and NCEs approvals, 1995-2003	61
Figure 3.11:	Strategies for analysis of toxicoproteomic data	66
Figure 3.12:	The impact of protein probes on drug discovery	72
Figure 4.13:	Three stages of diagnostic development	78
Figure 4.14:	The predicted individual response to any one drug	80
Figure 6.15:	Example of a 2-D PAGE gel	117
Figure 6.16:	Representation of liquid chromatography	119
Figure 6.17:	Typical high performance liquid chromatography set-up	122
Figure 6.18:	Representation of a 'sandwich' – type expression array	124
Figure 6.19:	A typical ESI instrument set up	130
Figure 6.20:	Simplified diagram of MALDI apparatus	132
Figure 6.21:	Representation of the yeast two hybrid system	135
Figure 6.22:	Schematic representation of FRET for investigating protein-protein interactions	136
Figure 6.23:	Representation of FRET for investigating protein-protein interactions	141
Figure 6.24:	Example of a pathway diagram from KEGG	142

## List of Tables

Table 1.1:	The single- and three-letter amino acid codes	23
Table 1.2:	The codons and the amino acids that they specify	27
Table 2.3:	Summary of key proteomics technologies	36
Table 2.4:	A selection of protein array manufacturers*	39
Table 2.5:	Automation of proteomic platforms	46
Table 2.6:	Summary of proteomics databases*	50
Table 3.7:	Constant dollar reduction in total cost per new drug, 2002	61
Table 3.8:	R&D spend on drug development, 2002	64
Table 3.9:	New biologics	69
Table 3.10:	Recombinant proteins	70
Table 3.11:	Protein drug targets	71
Table 3.12:	New proteomic targets	73

Table 4.13:	Proteomic biomarkers	78
Table 4.14:	Correlation of survival with HER-2 over-expression	82
Table 5.15:	Colloborations implementing proteomics technologies	100